Phase I Trial to Evaluate the Tolerance, Pharmacokinetics and Efficacy of the Broad-Spectrum ErbB Family Inhibitor Larotinib Mesylate in Patients With Advanced Solid Tumors

Ítems similars

• Tolerance, Variability and Pharmacokinetics of Albumin-Bound Paclitaxel in Chinese Breast Cancer Patients
  per: Li, Qingmei, et al.
  Publicat: (2018)
• A Phase I Clinical Study Comparing the Tolerance, Immunogenicity, and Pharmacokinetics of Proposed Biosimilar BAT1806 and Reference Tocilizumab in Healthy Chinese Men
  per: Zhang, Hong, et al.
  Publicat: (2021)
• A randomized phase-I pharmacokinetic trial comparing the potential biosimilar tocilizumab (QX003S) with the reference product (Actemra(®)) in Chinese healthy subjects
  per: Zhang, Hong, et al.
  Publicat: (2021)
• A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Ascending Dose and Food Effect Study to Evaluate the Tolerance, Pharmacokinetics of Jaktinib, a New Selective Janus Kinase Inhibitor in Healthy Chinese Volunteers
  per: Liu, Jingrui, et al.
  Publicat: (2020)
• ErbB2 expression increases the spectrum and potency of ligand-mediated signal transduction through ErbB4
  per: Wang, Ling-Mei, et al.
  Publicat: (1998)